Nicholas DeVito, Assistant Professor of Medicine at Duke University, Division of Medical Oncology, shared a post on LinkedIn:
“Very grateful for the opportunity to present our two concepts, one in the neoadjuvant setting and the other MRD+ CRC, neither of which have any standard of care option for patients. I opened to the audience with the reminder of the importance of investigator initiated trials, and how the K-SPY platform is transformative in this respect as well.
Most trials are not run by the physicians on the ground, who are seeing the patients and trying to come up with practical, scientifically justified solutions for them. In the hands of investigators, the patient is front and center. The Colorectal Cancer Alliance not only knows this but has done something to change it, empowering collaboration in the process.
The mission is obvious. The time is now. Let’s Cure Colorectal Cancer.”
More posts featuring Colorectal Cancer.